VIENNA—At the St Gallen Breast Cancer Conference BCL-2 was named as a therapeutic target for patients with hormone-receptor positive breast cancer by Geoffrey J Lindeman BSc(Med) PhD, from the University of Melbourne and the Walter and Eliza Hall Institute of Medical Research and head of the Familial Cancer Centre at The Royal Melbourne Hospital, Australia. He discussed the clinical potential of BCL-2 modulation with Oncology Times reporter Sarah Maxwell.
You may also like...
Longer Follow-up Reveals: Aspirin Prevents Cancer in Lynch Syndrome 28 Sep, 2009 No Prime Time Soon for Vaccines in Lung Cancer—Immune Suppression Reversal Urgently Needed 20 Apr, 2015 Preventing ER-Positive Breast Cancer—Latest from IBIS 1, 2 and 3 20 Mar, 2015 ‘Rescanning’ Optimizes Pencil Beam Proton Delivery to Moving Lung Tumor 12 May, 2015
- Previous story Tumor Microenvironment: Tumor Infiltrating Lymphocyte Score Predicts Breast Cancer Outcome
- Next story Targeting Bone Microenvironment in Breast Cancer
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014